GW Pharma Phase 3 Data Due Soon

The Financial Times shared a great history of the ups and downs  of GW Pharma (NASDAQ: GWPH), which will soon report the results of the first of four Phase 3 FDA clinical trials for its potential blockbuster drug for epilepsy, Epidiolex. The article discusses the shrewd move a few years ago to list its shares on the NASDAQ, which gave the company better access to capital.  CEO Justin Gover has moved to the U.S. subsequently.

This is what we’ve been working towards for 16 years. I’m excited but I wouldn’t be human if I didn’t have some nerves.

justin-gover

Justin Gover, CEO

Read Andrew Ward’s “Decisive moment looms for UK maker of medical marijuana”: http://www.ft.com/cms/s/0/39db3e7a-bab8-11e5-bf7e-8a339b6f2164.html#axzz3yvDvIAns

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter